Menu

CDC Director Resigns Over Unresolved Conflicts of Interest

Brenda Fitzgerald had drawn criticism for tobacco-related investments, among others.

Jan 31, 2018
Shawna Williams

FLICKR, RAED MANSOURFollowing a report by Politico that she had purchased shares in tobacco, pharmaceutical, and health insurance companies early in her tenure as director of the Centers for Disease Control (CDC), Brenda Fitzgerald resigned from the agency today (January 31). Fitzgerald had previously been criticized by Senator Patty Murray (D-WA) for financial investments that led her to recuse herself from involvement in some aspects of CDC’s work, The Washington Post reports.

See “Trump Administration Chooses New CDC Director

“You don’t buy tobacco stocks when you are the head of the CDC,” Richard Painter, a former chief ethics lawyer for George W. Bush, tells Politico. “It’s ridiculous; it gives a terrible appearance.”

According to a Department of Health and Human Services statement announcing the departure, “Dr. Fitzgerald owns certain complex financial interests that have imposed a broad recusal limiting her ability to complete all of her duties as the CDC Director. Due to the nature of these financial interests, Dr. Fitzgerald could not divest from them in a definitive time period.”

Before assuming the CDC post in July 2017, Fitzgerald had worked as an obstetrician-gynecologist. She had also served as a major in the Air Force and as chief of Georgia’s state health department.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.